摘要
目的评价^18F—FDG SPECT-CT在监测宫颈癌复发和（或）转移中的价值。方法回顾性分析为评估宫颈癌是否复发和（或）转移而行^18F—FDG SPECT-CT的62例患者的临床资料，以二次手术或局部活检病理或临床随访为最终结果，并与同期CT和鳞状细胞癌抗原（SCCA）检查结果对比。结果经病理或临床随访证实，62例患者中有36例复发和（或）转移。^18F-FDG SPECT—CT对宫颈癌复发和（或）转移监测的灵敏度、特异度、阳性预测值、阴性预测值及准确率分别为94．4％、92．3％、94．4％、92．3％、93．5％；CT分别为69．4％、80．8％、83．3％、65．6％、74．2％；SCCA检查分别为66．7％、46．2％、63．2％、50．0％、58．1％。结论^18F—FDG SPECT—CT监测宫颈癌复发和（鳓转移有较大临床价值。
Objective To evaluate the value of ^18F-fluorodeoxyglucose （lSF-FDG）SPECT-CT in detecting recurrence and（or） metastasis of cervical cancer. Methods Retrospective analysis of 62 patients who underwent ^18F-FDG SPECT-CT to evaluate recurrence and/or metastasis of cervical cancer at Fujian Tumor Hospital. The diagnostic results were confirmed by second surgery, biopsy or clinical follow-up, and also compared with the coincidence images obtained by CT scan and the serum squamous cell carcinoma related antigen （SCCA） levels. Results It is confirmed that 36 of 62 patients had recurrence and （or） metastasis of cervical cancer by biopsy or clinical follow-up. The sensitivity, specificity, positivity predieitive value （PPV）, negative predictive value （NPV）, and accuracy of lSF-FDG SPECT-CT were 94.4%, 92.3, 94.4%, 92.3% and 93.5%. Those of CT scan were 69.4%, 80.8%, 83.3%, 65.6% and 74.2%. Those of SCCA measurement were 66.7%, 46.2%, 63.2%, 50.0% and 58.1%. Conclusions ^18F-FDG SPECT-CT has greater clinical value to monitor recurrence and（or） metastasis of cervical cancer.
出处
《国际放射医学核医学杂志》
2010年第3期155-158,共4页
International Journal of Radiation Medicine and Nuclear Medicine
